Back to Agenda
Session 3: Performance of Clinical Trials during the Pandemic: Lessons Learned
Session Chair(s)
Nick Sykes, MS
Policy Advisor
EFPIA, Belgium
Rose-Marie Swallow
Senior Manager, Policy & Research
Bayer Plc., United Kingdom
The COVID pandemic had, and is continuing to have, a significant impact on our ability to run clinical trials. This panel discussion will outline some of the challenges that have been faced and some of the solutions that have been implemented to enable ongoing trials to continue and for new trials to be started. This session will also look at how some of these solutions could continue to be used in the post-pandemic setting.
Speaker(s)
Sponsors Perspective
Virginia Acha, PhD, MSc
Merck Sharp & Dohme LLC, United Kingdom
AVP, Global Regulatory Policy
Health Inspectorate Perspective
Brian Barnes, MA
BioNTech, United States
Director, Risk Management Strategy, Global Clinical Development Operations
Competent Authorities Perspective
Greet Musch, PhD
FAMHP, Belgium
strategic adviser
Investigator Side on a Current Clinical Trial
Ulrich Jaeger, DrMed
Medizinische Universität Wien, Austria
Professor
Have an account?